Compositions and Methods for the Treatment of Catatonia
OwnerJames Conourinventor
Life of this patent
Estimating the term…
Abstract
Compositions and methods for treating psychotic and neurological disorders in a subject are disclosed. The compositions and methods utilize a pharmaceutical compound that reverses or negates the effects of an NMDA receptor antagonist. The compositions and methods are effective in reducing at least catatonic features in the subject.
Claims20
A method of treating a psychotic or neurological disorder comprising catatonic features in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a pharmaceutical compound that reverses or negates the effects of an NMDA receptor antagonist for a period of at least about 2 weeks to decrease the subject's BFCRS score by at least 4.
A composition, comprising:
- a therapeutically effective amount of an antipsychotic agent;
- a therapeutically effective amount of a pharmaceutical compound that reverses or negates the effects of an NMDA receptor antagonist and reduces catatonic features in a subject having a psychotic or neurological disorder;
- and
- an optional therapeutically effective amount of a benzodiazepine.
A method of treating a subject for catatonic schizophrenia, comprising:
- administering a treatment regimen to the subject comprising
- a therapeutically effective amount of an antipsychotic agent selected from the group consisting of clozapine and olanzapine, and
- a therapeutically effective amount of a pharmaceutical compound that reverses or negates the effects of an NMDA receptor antagonist in the subject,
- wherein the treatment regimen comprises administering at least about 200 mg per day of the pharmaceutical compound to the subject for a period of at least about 1 month to result in a decrease in the subject's BFCRS score of about 15.
Dependencies are inferred from the claim text.